We recently compiled a list of the 10 Best Growth Stocks To Buy According To George Soros. In this article, we will look at ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second quarter 2024 ...

AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically ...

Johnson & Johnson's stock has seen modest gains in recent months. Read why I downgrade JNJ stock from buy to hold.

Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With ...

The AstraZeneca PLC ADR AZN slipped 1.58% to $77.14 Monday, on what proved to be an all-around great trading session for the ...

AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

Intel jumps on reports of Apollo investment and Qualcomm takeover interest, Palantir and Dell join the S&P 500, and TSMC and Samsung reportedly mulling UAE chip megafactories. Here's what investors ...

AstraZeneca PLC AZN shares dropped 1.66% to £115.84 Monday, on what proved to be an all-around great trading session for the ...

Datopotamab deruxtecan is a TROP2-directed DXd ADC engineered by Daiichi Sankyo and co-developed by AstraZeneca and Daiichi Sankyo. The data pertaining to this compound will be presented at an ...

Sweden stocks were higher after the close on Monday, as gains in the Oil & Gas, Telecoms and Industrials sectors led shares ...

The most recent trading session ended with Astrazeneca (AZN) standing at $78.38, reflecting a -0.66% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's ...